Evidence map›Paper›PMID 42137872›Full record

Trial reportFrontiers in nutrition2026

Impact of

Janie Parrino, Justine Sunshine, Kenneth Tripp, Michael Shaffer, Ume Sughra, Nicola Procházková, Marlene Jara, Janne Marie Moll, Robert Noble, Lori Muir and 6 more

Registry-linked trialAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05952076 (A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Bi-26), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05952076 phase3terminatednot on this map

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of Bi-26 (Strain of Bifidobacterium Longum, B. Infantis) Supplementation Versus Placebo on Weight Gain in Underweight Infants

TypeinterventionalSponsorGates Medical Research InstituteRan2023 to 2024Enrolled40ConditionsUnderweight, PaediatricsArmsB. infantis Bi-26, Placebo
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Janie Parrino *Gates Medical Research Institute, Clinical Development, Cambridge, MA, United States.
Justine Sunshine *Gates Medical Research Institute, Clinical Development, Cambridge, MA, United States.
Kenneth TrippGates Medical Research Institute, Clinical Development, Cambridge, MA, United States.
Michael ShafferGates Medical Research Institute, Clinical Development, Cambridge, MA, United States.
Ume SughraAl Shifa Research Centre, Rawalpindi, Punjab, Pakistan.
Nicola ProcházkováCmbio, Copenhagen, Denmark.
Marlene JaraCmbio, Copenhagen, Denmark.
Janne Marie MollCmbio, Copenhagen, Denmark.
Robert NobleGates Medical Research Institute, Clinical Development, Cambridge, MA, United States.
Lori MuirGates Medical Research Institute, Clinical Development, Cambridge, MA, United States.
Emily McIntyreGates Medical Research Institute, Clinical Development, Cambridge, MA, United States.
Elif GudukGates Medical Research Institute, Clinical Development, Cambridge, MA, United States.
Devika ZachariahGates Medical Research Institute, Clinical Development, Cambridge, MA, United States.
Cecile VernochetGates Medical Research Institute, Clinical Development, Cambridge, MA, United States.
Nicole FrahmGates Medical Research Institute, Clinical Development, Cambridge, MA, United States.
Alexander C SchmidtGates Medical Research Institute, Clinical Development, Cambridge, MA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Alterations in the gut microbiome are implicated in infant malnutrition. Methods: In this double-blind, randomized, placebo-controlled trial, 40 infants aged 30-120 days (d) with a weight-for-age Z score (WAZ) below -2 received daily oral Bi-26 or placebo for 28d, with follow-up to d90 for safety. The primary endpoint was change in WAZ from baseline to d56. The intended sample size was 396 infants but study was terminated early due to operational delays. Total Results: Bi-26 supplementation increased fecal Discussion: Bi-26 supplementation had an acceptable safety profile but did not improve growth. The findings of this trial support further evaluation of Clinical trial registration: https://www.clinicaltrials.gov/study/NCT05952076, NCT05952076.

Indexed as

Bifidobacterium infantisbiomarkersmalnutritionmetabolomicsmetagenomicsmicrobiomeprobiotic

Identifiers

PMID42137872
PMCPMC13167951

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.